利什曼病疫苗研究进展（待续）  

Advance in research on leishmaniasis vaccines （ to be continued）

作　　者：孙柯(综述)[1] 陈建平(综述)[1] 

机构地区：[1]四川大学华西基础医学与法医学院寄生虫学教研室,成都610041

出　　处：《国际生物制品学杂志》2013年第1期22-25,共4页International Journal of Biologicals

基　　金：基金项目：国家自然科学基金（81171607）

摘　　要：利什曼病是一种媒介传播的寄生虫病，由不同种属的利什曼原虫感染引起。利什曼病流行于全球88个国家，约3．5亿人受到威胁。目前治疗利什曼病的主要方法是化学疗法，但毒性和耐药性阻碍了其应用，因此急需开发出一种安全有效的利什曼病疫苗。尽管在过去的几十年，发现了许多利什曼原虫抗原，但仅少部分疫苗在临床试验阶段取得进展。此文就利什曼病疫苗的研究进展进行综述。Leishmaniasis is a vector-borne parasitic disease caused by different species of the genus Leishmania, and is endemic in 88 countries on a global scale, threatening approximately 350 million people, Chemotherapy is a main mean to treat leishmaniasis at present, but the toxicity and drug resistance hamper its application. Therefore, it is urgent to develop safe and effective leishmaniasis vaccines. In the past decades, numerous antigen candidates of Leishmania have been found, but the research progress in clinical trial has been made only in a few vaccines. The advance in research on leishmaniasis vaccines is reviewed.

关 键 词：利什曼原虫属 利什曼原虫疫苗 抗原 

分 类 号：R979.5[医药卫生—药品]